0001127602-15-020743.txt : 20150616 0001127602-15-020743.hdr.sgml : 20150616 20150616153241 ACCESSION NUMBER: 0001127602-15-020743 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150513 FILED AS OF DATE: 20150616 DATE AS OF CHANGE: 20150616 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Barnes Alane P CENTRAL INDEX KEY: 0001584348 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 15934268 MAIL ADDRESS: STREET 1: 1929 BRASSFIELD ROAD CITY: RALEIGH STATE: NC ZIP: 27614 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2015-05-13 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001584348 Barnes Alane P 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 VP, General Counsel & Corp Sec Emp. Stock Option (Right to Buy) 5.45 2015-05-13 4 A 0 17000 0 A 2015-05-13 2023-08-08 Common Stock 17000 17000 D On May 13, 2015, BioCryst Pharmaceuticals, Inc. initiated a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on May 13, 2015. /s/ Alane P. Barnes 2015-06-16